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OsteoclastOsteoporosis is amajor public health issue that is expected to rise as the global population ages. Resveratrol (RES)
is a plant polyphenol with various anti-aging properties. RES treatment of bone cells results in protective effects,
but dose translation from in vitro studies to clinically relevant doses is limited since bioavailability is not taken
into account. The aims of this review is to evaluate in vivo evidence for a role of RES supplementation in promot-
ing bone health to reduced osteoporosis risk and potential mechanisms of action. Due tomultiple actions on both
osteoblasts and osteoclasts, RES has potential to attenuate bone loss resulting from different etiologies and
pathologies. Several animal models have investigated the bone protective effects of RES supplementation.
Ovariectomized rodent models of rapid bone loss due to estrogen-deﬁciency reported that RES supplementation
improved bonemass and trabecular bone without stimulating other estrogen-sensitive tissues. RES supplemen-
tation prior to age-related bone loss was beneﬁcial. The hindlimb unloaded rat model used to investigate bone
loss due to mechanical unloading showed RES supplementation attenuated bone loss in old rats, but had
inconsistent bone effects in mature rats. In growing rodents, RES increased longitudinal bone growth, but had
no other effects on bone. In the absence of human clinical trials, evidence for a role of RES on bone heath relies
on evidence generated by animal studies. A better understanding of efﬁcacy, safety, and molecular mechanisms
of RES on bone will contribute to the determination of dietary recommendations and therapies to reduce
osteoporosis. This article is part of a Special Issue entitled: Resveratol: Challenges in translating pre-clinical ﬁnd-
ings to improved patient outcomes.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Resveratrol (RES) is a polyphenolic (3,4′,5-trihydroxystilbene)
compound naturally present in red wine and a variety of plant foods
such as grapes, cranberries, and nuts [1]. There is a growing body of
evidence that RES is an effective therapeutic agent for age-related
degenerative diseases such as osteoporosis [2,3]. Osteoporosis is a
skeletal disorder characterized by low bone mass, structural deteriora-
tion, decreased bone strength, and increased risk of bone fractures
[4]. Osteoporosis is a major public issue with a worldwide estimated
9 million bone fractures annually. Additionally, the prevalence of
osteoporosis is expected to increase as the global population ages
[5].
Throughout life, bone is remodeled by a process involving bone
resorption which removes old bone followed by replacement with
new bone by the process of bone formation. During the growth stagesl: Challenges in translating pre-of childhood, adolescence, and into young adulthood, bone formation
exceeds the rate of bone resorption resulting in bone mass acquisition.
After this stage, at ~20–30 years of age, bone resorption exceeds bone
formation resulting in gradual and progressive bone loss [6]. Therefore,
maximizing peak bone mass (PBM) during the growth stage is an
important factor for preventing future risk of osteoporosis. This is
particularly important for women,who are at greater of risk of osteopo-
rosis thanmen, due to rapid bone loss resulting from declining estrogen
at menopause [7]. Both women and men experience age-related bone
loss that is often accelerated by mechanical unloading associated with
physical inactivity and prolonged bed rest [8]. Disuse-related bone loss
is also observed in young patients conﬁned to prolonged bed rest as a
result of injury or immobilization due to spinal cord injury.
RES has estrogenic, anti-inﬂammatory, antioxidant, and proliferative
properties that can inﬂuence bonemetabolism [9]. No toxicity has been
reported for RES intakes of up to 500 mg/d in animals and humans [9,
10]. Due to its multiple bioactivities and low toxicity, RES offers the
promise of being an efﬁcacious and safe therapeutic agent for osteopo-
rosis. However, due to the lack of human clinical trials, evidence of a
therapeutic role of RES on bone relies on in vitro studies and animal
models of bone loss. The aim of this review is to evaluate the pre-
clinical evidence of RES supplementation to enhance bone, to reduce
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better understanding of the effects of RES on bone will contribute
toward the development of dietary recommendations and therapies
for preventing bone loss leading to osteoporosis.2. Bone remodeling
Bone consists of cortical (compact) and trabecular (spongy)
components. Cortical bone accounts for ~80% of skeletal mass and
is located in the diaphyseal regions of long bones; whereas, trabecu-
lar bone is located inside cortical bone in the proximal and distal
epiphysis region of long bones and vertebrae [6] (Fig. 1A). Bone is
constantly remodeled in a process where old bone is removed
(bone resorption) and replaced by new bone (bone formation). The
process of bone remodeling is summarized in Fig. 1B. The cell line-
ages important in bone turnover are osteoblasts and osteoclasts
[11]. Osteoclasts are derived from hematopoietic progenitors (i.e.
monocyte/macrophage) in the bone marrow. Receptor activator of
nuclear kappa B ligand (RANKL) produced by osteoblasts bound to
RANK receptors located on the surface of hematopoietic cells pro-
motes differentiation into osteoclasts [11]. Activated osteoclasts
attach to the bone surface and release proteolytic enzymes that di-
gest connective tissue proteins and solubilize bone mineral. Produc-
tion of enzymes such as tartrate-resistant acid of the phosphatase
(TRAP) and collagen degradation products such as deoxypyridinoline
(DPD) and C-terminal telopeptide of type I collagen (CTX) during
osteoclastogenesis provides useful surrogate clinical markers of bone
resorption. To counterbalance bone resorption, osteoblasts also produce
osteoprotegerin (OPG) that inhibit osteoclastogenesis by binding to
RANKL and blocking interaction with the RANK receptor [12]. Osteo-
blasts ﬁll the cavity produced by osteoclast-mediated resorption by
synthesizing and mineralizing new bone [11]. Hence, skeletal integrity
requires a balance between bone-forming osteoblast activity andFig. 1. Summary of steps in normal bone remodeling and the results of imbalances in bone turno
C) bone loss and acquisition due to alterations in bone formation and bone resorption. Symbol
Adapted from the University of Michigan bone remodeling http://www.umich.edu/news/Relea
m46281/latest/.bone-resorbing osteoclast activity. Imbalances where bone resorption
exceeds formation result in bone loss [12].
Osteoporosis is the result of increased osteoclast activity and/or de-
creased osteoblast activity during remodeling. Osteoblasts are õderived
from pluripotent mesenchymal stem cells (MSCs) in the bone marrow.
MSCs differentiate into either osteoblasts, adipocytes or chondrocytes
depending on the activation of speciﬁc transcription factors [11].
Expression of the transcription factor, peroxisomeproliferator activated
receptor gamma (PPARγ), is the main determinant of MSC differentia-
tion into adipocytes [13]. Several transcription factors are required for
MSC differentiation into osteoblasts. Runt-related transcription factor
2 (Runx2) is considered the master regulator of osteoblast differentia-
tion [14] and Osterix downstream of Runx2 is also essential [15].
MSCs committed to the osteoblast lineage form osteoprogenitors.
Entering a proliferation phase, osteoprogenitors undergo morphologi-
cal changes into pre-osteoblasts that are capable of synthesizing bone
matrix and alkaline phosphatase (ALP) [11]. Pre-osteoblasts mature
into osteoblasts that regulate bone matrix mineralization and produce
osteocalcin [11]. Circulating ALP and osteocalcin provide useful
surrogate clinical markers of bone formation. Osteoblast differentiation
ends with the formation of osteocytes that regulate bone responses to
mechanical stimuli and bone mineralization [16] (Fig. 1B).
The activity of transcription factors can be inﬂuenced by various
local and systemic factors that include bone morphogenetic proteins
[17], insulin-like growth factor (IGF) [18], the canonical wingless
(Wnt)/β-catenin signaling pathway [19], mechanical forces [20], estro-
gen and other hormones [21]. The natural food component RES has both
structural and functional similarities to estrogen [22]. Furthermore, die-
tary RES activates Sirtuin1 (Sirt1) known as the longevity gene [23].
Bäckesjö et al. [24] reported that Sirt1 activation decreases MSC
differentiation into adipocytes while promoting differentiation into
osteoblasts. Much of the knowledge about molecular mechanisms
underlying RES as a dietary treatment for osteoporosis has been derived
from in vitro studies.ver. A) femur anatomical sites, B) cell lineages involved in the process of bone remodeling,
↓ decrease, ↑ increase, ↑↑ predominant.
ses/2005/Feb05/bone.html and Openstax College bone structure http://cnx.org/content/
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Mobasheri and Shakibaei [25] reviewed evidence from in vitro
studies conducted using immortal tumor-derived cells, primary MSCs,
pre-osteoblasts, and osteoclast progenitors concluded that RES
enhanced bonemass by promoting osteoblastogenesis and by inhibiting
osteoclastogenesis. Therefore, RES may have advantages over current
pharmacological therapies which act either by promoting osteoblast-
mediated bone formation or by inhibiting osteoclast-mediated bone
resorption. Multiple actions include direct stimulation of osteoblast
proliferation and differentiation indicated by increased DNA synthesis
and ALP activity in RES-treated osteoblastic MC3T3-E1 cells. The ability
of the anti-estrogenic drug, tamoxifen to antagonize these effects
indicated that RES stimulated osteoblastogenesis by acting as an estro-
gen agonist [26]. Dai et al. [27] demonstrated that treating human
bone marrow-derived MSC with RES increased gene expression of the
key osteogenic transcription factors, Runx2 and Osterix. RES was also
demonstrated in vitro to act on various signal transduction pathways.
RES activated the estrogen-mediated extracellular signal-regulated
kinase (ERK) 1/2 signaling pathway regulating osteoblast differentia-
tion and proliferation [27]. RES activated AMP-activated protein kinase
(AMPK) which regulates osteoblast differentiation and inhibits bone
resorption by acting as a negative regulator of RANKL [28]. Zhou et al.
[29] showed that RES augmented Wnt signaling which stimulated
osteoblastogenesis and bone formation. Treating human bone
marrow-derivedMSCwith RES promoted differentiation ofMSC toward
osteoblasts by up-regulating Runx2 gene expression through the
activation of Sirt1 [30,31]. Also, activation of Sirt1 by RES was shown
to promote binding to PPARγ which repressed MSC differentiation
into adipocytes [24,32]. Additionally, RES suppresses osteoclastogenesis
by acting through Sirt1 to bind to RANK which inhibited binding to
RANKL [11,33]. Potential molecular mechanisms underlying RES effects
on bone are summarized in Fig. 2.Fig. 2. Schematic of potential molecular mechanisms of resveratrol on osteoblasts and osteoc
collagen; DPD, deoxypyridinoline; ERK, extracellular signal-regulated kinase 1/2; NFκB, nu
tartrate-resistant acid of the phosphatase; Wnt; canonical wingless/β-catenin signaling pathw
Adapted from Openstax College bone structure http://cnx.org/content/m46281/latest/.Based on evidence derived from in vitro studies, RES by acting on
both osteoblasts and osteoclasts offers a promising natural therapeutic
agent for osteoporosis. Whether effects on bone cells translate to bone
tissue cannot be determined in vitro. Also, cell culture systems do not
take bioavailability into account. In vivo evidence indicates that
RES has low bioavailability due to rapid metabolism in the body [34].
Therefore, this review focuses on evaluating pre-clinical evidence of
RES supplementation to enhance bone, prevent osteoporosis, and to de-
termine potential mechanisms.
4. Animal studies
The pathophysiology of osteoporosis differs depending on the
etiology. Age-related osteoporosis produces gradual bone loss that is
predominantly due to reduced osteoblasts; whereas, postmenopausal
osteoporosis produces rapid bone loss that is predominantly due to
increased osteoclast activity [7] (Fig. 1C). The therapeutic value of RES
has been investigated using various animal models that include
the ovariectomized (OVX) animal model of rapid bone loss due to
estrogen-deﬁciency and the hindlimb unloaded (HLU) animal model
of bone loss due to mechanical unloading. Animals of varying ages
have been used in order to determine the effects of providing RES
during the growth stage on PBM and during aging on bone loss associ-
ated with senile osteoporosis.
4.1. Resveratrol and estrogen deﬁciency-related bone loss
Declining estrogen is a major risk factor in osteoporosis [35]; there-
fore, hormone or estrogen replacement therapy (ERT) has been used as
treatments. However, ERT has serious side effects which include
increased risk of cardiovascular disease, breast cancer, and uterine can-
cer [36,37]. In vitro, RES has been shown to exert estrogenic as well as
estrogenic-independent effects on bone cells [25]. In a pre-clinicallasts. Abbreviations are ALP, alkaline phosphatase; CTX, C-terminal telopeptide of type I
clear factor kappa B; Runx2, runt-related transcription factor 2; Sirt1, Sirtuin1; TRAP,
ay.
Table 1
Summary of pre-clinical studies of resveratrol supplementation on bone mineralization, microarchitecture, strength, growth, and remodeling in different rodent models.
Authors Treatment Bone results Bone remodeling
Estrogen-deﬁciency bone loss models
Liu et al. [38] OVX Wistar rats (n = 11/group) ↑femur epiphysis BMD
Age: ~2.5 months ↑femur Ca
RES dose: 0.7 mg/kg bwt/d
Duration: 12 weeks
Mizutani et al. [40] OVX SHRSP/Izm rats (n = 6/group) NS femur Ca Preserved bone protein matrix indicated by
↑femur hydroxylprolineAge: 4 months ↑femur breaking energy
RES dose: 5 mg/kg bwt/d
Duration: 8 weeks
Sehmisch et al. [42] OVX Sprague–Dawley rats (n = 11/group) NS tibia total BMD
Age: 3 months NS tibia cortical bone
RES doses: 5, 50 mg/kg bwt/d NS tibia trabecular bone
Duration: 12 weeks NS tibia bone strength
Lin et al. [43] OVX Sprague–Dawley rats (n = 8/group) ↑femur BMD 15, 45 mg/kg bwt/d RES Promoted bone formation indicated by
↑serum ALP
NS serum TRAP
Age: 3 months ↑tibia BMD 45 mg/kg bwt/d RES
RES doses: 5, 15, 45 mg/kg bwt/d ↑vertebrate BMD all doses
Duration: 13 weeks
Zhao et al. [45] OVX Wistar rats (n = 10/group) ↑femur neck BMD 40, 80 mg/kg bwt/d
RES
Suppressed inﬂammation indicated by
↓femur IL-6, TNFα
Age: 3–4 months ↑femur distal BMD 80 mg/kg bwt/d RES
RES doses: 20, 40, 80 mg/kg bwt/d ↑femur trabecular bone 40,
80 mg/kg bwt/d RESDuration: 12 weeks
Age-related bone loss models
Tresguerres et al. [51] Male Wistar rats (n = 10/group) ↑cortical bone NS plasma osteocalcin
NS plasma CTXAge: 22 months ↑trabecular bone
RES doses: 10 mg/kg bwt/d
Duration: 10 weeks
Durbin et al. [53] HLU male Fisher 344 × Brown Norway rats NS bone mass Suppressed inﬂammation & promoted bone formation
indicated by
↑serum C-reactive peptide
↑serum osteocalcin and ALP
NS TRAP, DPD, and CTX
(n = 6–7/group) ↑femur P content
Age: 33 months ↑tibia trabecular connectivity
RES dose: 12.5 mg/kg bwt/d NS bone strength
Duration: 3 weeks
Pearson et al. [54] Male C57BL/6NIA mice (n = 8–10/group) ↑femur trabecular bone
Age: 12 months ↑femur cortical bone
RES dose: 8 and 31 mg/kg bwt/d ↑femur strength
Duration: 18 months
Bone acquisition models
Turner et al. [58] Female Sprague–Dawley rats (n = 5–6) NS cross-sectional growth
measurementsAge 21 d
RES dose: 1,4,10,40,100 μg/d
Duration: 6 d
Karimian et al. [61] Female New Zealand white rabbits (n = 12/group) ↑tibia and vertebrae length Suppressed vascularization indicated by
↓VEGF
↓laminin
Age: 12 weeks ↑tibia chondrocytes
RES dose: 200 mg/kg bwt/d ↑growth plate area
Duration: 16 weeks ↓growth plate fusion
Durbin et al. [62] Male Fisher 344 × Brown Norway rats (n = 7/group) ↑tibia length and width Suppressed inﬂammation indicated by
↓plasma C-reactive peptideAge: 6 months NS tibia mineralization
RES dose: 12.5 mg/kg bwt/d NS tibia microarchitecture
Duration: 3 weeks
Chen et al. [64] Male Sprague–Dawley rats (n = 6/group) ↑spine, femur, whole body bone mass Suppressed inﬂammation & promote bone formation
indicated by
↓serum TNFα
↑serum osteocalcin
Age: 6 weeks
RES dose: 100 mg/kg bwt/d
Duration: 8 weeks
Disuse bone loss models
Durbin et al. [53] HLU male Fisher 344 × Brown Norway rats ↑femur mineralization Suppressed inﬂammation & promote bone formation
indicated by
↓serum TNFα
↑plasma ALP and osteocalcin
NS plasma TRAP, DPD, CTX
(n = 6–7/group) ↑femur trabecular bone
Age: 33 months NS femur cortical bone
RES dose: 12.5 mg/kg bwt/d ↑femur strength
Duration: 3 weeks (1 week prior, 2 weeks during HLU) ↑tibia bone mass
↑tibia trabecular bone
↑tibia cortical area
NS tibia strength
Durbin et al. [62] HLU male Fisher 344 × Brown Norway rats
(n = 7/group)
NS femur mineralization Promote oxidation & decrease osteoblasts indicated by
↑plasma lipid peroxidation
↓plasma osteocalcinAge: 6 months NS femur cortical bone
RES dose: 12.5 mg/kg bwt/d NS femur trabecular bone
Duration: 3 weeks (1 week prior, 2 weeks during HLU) NS femur strength
↓tibia mineralization
↓cortical bone
NS trabecular bone
Habold et al. [74] HLU male Wistar rats (n = 5/group) ↑femur BMD
Age: 5 months ↑femur distal trabecular bone
RES dose: 400 mg/kg bwt/d NS femur cortical bone
(continued on next page)
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Table 1 (continued)
Authors Treatment Bone results Bone remodeling
Disuse bone loss models
Duration: 6.5 weeks (4.5 weeks prior, 2 weeks during HLU) ↑tibia BMD
↑tibia proximal trabecular bone
NS tibia cortical bone
Momken et al. [75] HLU male Wistar rats (n = 6–7/group) ↑femur BMD Promoted bone formation & suppressed bone
resorption indicated by
↑plasma osteocalcin
↓urinary DPD
Age: ~4.5 months ↑femur strength
RES dose: 400 mg/kg bwt/d
Duration: 6 weeks (4 weeks prior, 2
weeks during HLU)
Wang et al. [79] Spinal cord injured male Sprague–Dawley rats
(n = 10–12/group)
↑tibia bone mass Promote bone formation & suppress bone
resorption indicated by
↑plasma osteocalcin
↓urinary DPD
↑bone osteoblast surface
↓bone osteoclast surface
↑femur osteocalcin gene expression
↓femur TRAP gene expression
Age: 6 weeks ↑tibia trabecular bone
RES dose: 400 mg/kg bwt/d ↑femur strength
Duration: 10 d
Casarin et al. [82] Calvarial defect male Wistar rats (n = 15/group) ↓calvarial defect Promote bone maturation & ossiﬁcation
indicated by
↑calvarial sample BMP
↑calvarial sample osteopontin
Age: 2.5 months ↑retention of implants
RES dose: 10 mg/kg bwt/d
Duration: 30 d
Abbreviations: ALP, alkaline phosphatase; BMC, bone mineral content; BMD, bonemineral density; BMP, bonemorphogenetic protein; Ca, calcium; CTX, C-terminal telopeptide of type I
collagen; DPD, deoxypyridinoline; HLU, hindlimb unloaded; IL-6, interleukin-6; OVX, ovariectomized; NS, statistically non-signiﬁcant; RES, resveratrol; SHRSP, spontaneously hyperten-
sive stroke prone; TNFα, tumor necrosis factor alpha; TRAP, tartrate-resistant acid of the phosphatase, VEGF, vascular endothelial growth factor.
Habold et al. [74]
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0.7 mg/kg bwt RES for 12 weeks. RES attenuated OVX-induced loss of
femur calcium (Ca) and epiphyseal bone mineral density (BMD),
but not BMD loss in the mid-diaphysis (Table 1). The femur mid-
diaphysis consists predominantly of cortical bone while the epiphysis
consists predominantly of trabecular bone which is more sensitive to
estrogen deﬁciency [39]. Another study providing a higher dose of
5 mg/kg bwt/d RES in the diet for a shorter-duration of 8 weeks to
mature spontaneously hypertensive stroke prone OVX Izm rats showed
no signiﬁcant effect on femur Ca content and bone breaking load
strength, but preserved breaking energy [40], a strength measurement
that takes into account stiffness provided by minerals and toughness
provided by collagen in the bonematrix [41]. OVX rats provided dietary
RES improved bone collagen indicated by signiﬁcantly higher femur
hydroxyproline content (Table 1).
In contrast, Sehmisch et al. [42] reported that mature OVX Sprague–
Dawley rats provided diets supplemented with 5 or 50 mg/kg bwt/d
RES for a duration of 12 weeks had no effect on tibiae total BMD, cortical
or trabecular bone, and bone strength (Table 1). The absence of effects
may be because other estrogenic compounds were controlled in this
study by providing a phytoestrogen-free diet and RES has been reported
to have synergistic effects when combined with other phytochemicals
[25]. Also, bone measurements were performed on the tibia rather
than the femur. Lin et al. [43] performed measurements on both the
femur and tibia of mature OVX Sprague–Dawley rats fed 0, 5, 15 or
45 mg/kg bwt/d RES or ERT (0.03 mg/kg bwt diethylstilbestrol) in the
diet for 13 weeks. At the higher doses of 15 and 45 mg/kg bwt/d, RES
attenuated BMD loss in whole femur and in estrogen sensitive regions
of the femur. The highest (45 mg/kg bwt/d) RES dose completely
prevented OVX-induced whole tibial BMD loss. All doses of RES
prevented OVX-induced BMD loss in vertebrae, a site consisting pre-
dominantly of trabecular bone. RES effects on bone were equal to ERT
and RES had no adverse effects on the uterus indicated by the absence
of endometrial hyperplasia (Table 1). Estrogen deﬁciency bone loss is
due to increased osteoclastic activity without a corresponding increase
in osteoblastic activity [44] (Fig. 1C). Lin et al. [43] reported that provid-
ing RES to OVX rats promoted bone formation indicated by higher
serum ALP, but had no effect on the bone resorption marker, TRAP.
More recently, Zhao et al. [45] investigated RES supplementation on
bone includingmechanistic studies. OVXWistar rats were administered
RES doses of 0, 20, 40 or 80 mg/kg bwt/d or ERT (0.8 mg/kg bwt
estradiol valerate) by a stomach tube for a duration of 12 weeks. Inagreement with other studies, RES supplementation had no signiﬁcant
effect on femur diaphysis BMD, but was protective at the trabecular
bone sites. RES doses of 40 and 80 mg/kg bwt/d preserved BMD at the
femoral neck while the highest dose of 80 mg/kg bwt/d preserved
BMD at the distal femur (Table 1). RES doses of 40 and 80 mg/kg bwt/d
also protected against OVX-induced structural deterioration indicated
by preservation of trabecular area, thickness, and number. The highest
RES dose produced a similar degree of decreased trabecular spacing as
ERT. A dose-dependent down-regulation of femur gene expression of
OPG and cytokines, interleukin-6 and tumor necrosis factor alpha
(TNFα) indicated that RES reduced bone resorption by inhibiting signal-
ing pathways regulating RANKL. In vitro, primary bone cells isolated
from the femoral heads of canine bone fragments treated with RES
inhibited RANKL-induced activation of nuclear factor of kappa B
(NFκB), a key transcription factor regulating inﬂammation [33].
Collectively, the OVX rodent model showed that RES supplementa-
tion protected against estrogen deﬁciency induced bone mass loss and
trabecular structure deterioration (Table 1). High doses of RES produced
effects similar to ERTwithout stimulating endometrial hyperplasia. Pre-
clinical evidence supports the therapeutic value of RES in estrogen-
deﬁciency bone loss, but senile osteoporosis differs from postmeno-
pausal osteoporosis since both male and females are affected and bone
loss is gradual [7]. As the population ages, morbidity, mortality, and
the ﬁnancial costs attributed to osteoporosis are expected to increase
[46]. Therefore, it is important to determine an efﬁcacious and safe
therapy for age-related bone loss.
4.2. Resveratrol and age-related bone loss
In postmenopausal osteoporosis, trabecular bone loss predisposes
women to spine and wrist factures; whereas, in senile osteoporosis,
cortical bone loss predisposes the elderly to hip fractures [47,48]. Age-
related bone loss is due to reduced osteoblasts more than greater
osteoclast activity which characterizes estrogen-deﬁciency bone loss
[35] (Fig. 1C). During aging there is an accumulation of adipocytes at
the expense of osteoblasts in the bone marrow [7,49]. Increased adipo-
cytes in bone results in oxidative stress due to higher susceptibility to
lipid oxidation [7][49]. In vitro, RES treatment of murine osteoclast
progenitors suppressed RANKL-induced osteoclast differentiation by
inhibiting reactive oxygen species production [50].
In a pre-clinical study, Tresguerres et al. [51] provided male Wistar
rats 10 mg/kg bwt/d RES for a duration of 10 weeks. Enhanced bone
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becular bone volume and number, and reduced trabecular spacing
(Table 1). However, there were no signiﬁcant effects on bone turnover
markers, plasma osteocalcin and CTX. Rats were 22 months old at the
start of the study and age-related bone loss does not occur in the long
bones of male rats until age 24–27 months [52]. To investigate the efﬁ-
cacy of RES in age-related bone loss, Fischer 344 × Brown Norwaymale
rats aged 33 months were provided a daily oral gavage of 12.5 mg/kg
bwt RES [53]. Old rats provided RES showed no signiﬁcant effects on
BMD, bone mineral content (BMC), bone mineral area (BMA), and
strength, but increased femurphosphorus (P) content and tibia trabecular
connectivity. The RES supplementation duration of 3 weeks was short. In
a longer study, male C57BL/6NIA mice (age 12 months) were provided a
phytoestrogen-free diet supplementedwith 8 or 31 mg/kg bwt/d RES for
18 months [54]. Feeding RES improved whole femur trabecular tissue
mineral density and bone volume per unit of total volume (BV/TV).
Pooling of RES groups to increase statistical power from n = 4–5 to
8–10 mice/group resulted in signiﬁcantly higher femur trabecular thick-
ness, cortical tissue mineral density, and bone strength. Based on the
results of these few studies in different ages and species, RES supplemen-
tation prior to age-related bone loss over a long-duration enhanced long
bone microstructure (Table 1). To determine potential mechanisms,
Durbin et al. [53] assessed oxidative stress, inﬂammation, and bone turn-
over. There was no signiﬁcant effect on serum measurement oxidative
stress. Anti-inﬂammatory actions of RES supplementation in old male
rats were indicated by reduced serum C-reactive peptide concentration
which preserved osteoblasts as indicated by higher serum osteocalcin
and ALP concentrations, but no effects on bone resorption markers,
TRAP, DPD, and CTX.
Low bone mineral mass in the elderly is a function of the amount of
bone loss due to aging and insufﬁcient PBM attainment during skeletal
growth [35]. Epidemiological studies indicated that a 10% increase in
PBM can reduce bone fracture risk in postmenopausal women by 50%
[55,56]. Therefore, maximizing PBM during the bone acquisition stage
is important for preventing future risk of osteoporosis.
4.3. Resveratrol and bone acquisition
Skeletal growth involves both longitudinal and cross-sectional
growth. Periosteal cortical bone formation coupled with endosteal cor-
tical bone resorption regulates cross-sectional bone growth [57]. To
study bone growth, weanling female Sprague–Dawley rats were ran-
domly assigned to a daily oral gavage of 0, 1, 4, 10, 40, 100 μg/d RES or
estradiol (100 μg/d) dissolved in ethanol for a duration of 6 d. Despite
estrogenic activity, RES had no signiﬁcant effect on tibia cross-
sectional area, medullary area, cortical bone area, periosteal bone for-
mation rate or periosteal mineral apposition rate [58] (Table 1).
Lengthening of vertebrae and long bones is regulated by chondro-
cyte proliferation in the epiphyseal growth plate. Therefore, longitudi-
nal growth ceases upon growth plate fusion [59]. In vitro, RES
treatment of chondrocytes obtained from an adult rat femur protected
against the catabolic effect of pro-inﬂammatory cytokine, interleukin-
1β [60]. To determine the effects of RES on longitudinal growth
in vivo, Karimian et al. [61] provided a daily oral gavage of 200 mg/kg
bwt RES to pubertal female New Zealand white rabbits until growth
plate fusion occurred. After 16 weeks, rabbits provided RES supplemen-
tation had longer tibia and vertebrae,more chondrocytes, and increased
growth plate area compared to control rabbits (Table 1). RES supple-
mentation delayed growth plate fusion by suppressing the replacement
of avascular cartilage with vascularized bone indicated by the down-
regulated gene expression of vascular endothelial growth factor, a sig-
naling molecule in vascularization, and laminin, a cartilage protein.
In rabbits and humans, the epiphyseal growthplate fuses at sexualmat-
uration, but in rats andmice longitudinal bone growth continues after sex-
ual maturation [59]. Mature (age 6 months) male Fischer 344 × Brown
Norway rats provided a daily oral gavage of 12.5 mg/kg bwt RES for3 weeks had lengthened tibiae [62]. Anti-inﬂammatory actions of RES indi-
cated by reducedplasmaC-reactive peptide concentration prevented chon-
drocyte destruction. The absence of RES effects on femur longitudinal
growth may be due to slower growth compared to the tibia [63]. Despite
enhanced tibia length and width there was no signiﬁcant effects on bone
mineralization and microarchitecture (Table 1).
The role of RES supplementation on PBM remains unclear due to in-
consistent study ﬁndings and the fewpre-clinical studies that have been
conducted to date. However, Chen et al. [64] found beneﬁcial effects of
RES supplementation on bone following nutritional deprivation during
the growth stage. Immature male Sprague–Dawley rats were restricted
to 60% of their typical food intake. After 4 weeks, rats were randomly
assigned to be re-fed a normal (14% kcal) or high (59% kcal) fat diet sup-
plementedwith a daily oral gavage of 100 mg/kg bwt RES for a duration
of 8 weeks. Providing RES reversed spine, femur, and whole body BMD,
BMC, and BMA losses due to caloric restriction (Table 1). Catch-up
growth was more effective when RES was provided a normal versus a
high fat diet. The anti-inﬂammatory actions of RES preserved osteo-
blasts indicated by reduced serum TNFα concentration and enhanced
bone formation indicated by higher serum osteocalcin concentration.
Based on the Chen et al. [64] study, RES supplementation may be bene-
ﬁcial for treating secondary osteoporosis characterized by bone loss due
to conditions such as nutritional deﬁciencies, inactivity, bed-rest, and
immobilization.
4.4. Resveratrol and disuse-related bone loss
Mechanical unloading due to bed rest, paralysis, and microgravity
accelerates bone loss in weight-bearing bones [65]. Bone loss related
tomechanical unloading has been attributed to suppression of bone for-
mation and to the stimulation of bone resorption [8]. Aguirre et al. [66]
showed that mechanical unloading ofmice increased osteocyte apopto-
sis in cortical and trabecular bone which then acted as a signal for oste-
oclast recruitment resulting in bone resorption and bone loss. The
deleterious effects of mechanical unloading on bone were attributed
to increased reactive oxygen species and pro-inﬂammatory cytokines
[67]. Nakamura et al. [68] reported that inhibiting NFκB activity
prevented bone loss in mechanically unloaded mice. In vitro, suppress-
ing NFκB in osteoclast precursors decreased bone resorption by
inhibiting RANKL [68]. Thus, due to its anti-inﬂammatory and antioxi-
dant properties, RES has the potential to be an effective therapy for
disuse-related bone loss.
4.4.1. Mechanical unloading
In the elderly, decreased mechanical loading due to inactivity and
bed rest accelerates age-related bone loss [8]. To investigate the effects
of RES supplementation, rats were subjected to HLU, a model that has
been reported to induce similar bone changes as bed rest in humans
[69]. Durbin et al. [53] provided old male Fisher 344 × Brown Norway
rats a daily oral gavage of 12.5 mg/kg bwt RES for 1 week prior to
HLU and throughout the 2 weeks of HLU. RES supplementation
ameliorated femoral BMD, BMC, Ca, and P loss due to mechanical
unloading (Table 1). RES supplementation also protected against
microarchitectural deterioration indicated by complete prevention
of decreased femoral trabecular number and partial prevention of
decreased trabecular BV/TV and increased trabecular separation in-
duced by mechanical unloading. There were no signiﬁcant effects
on cortical bone. During mechanical loading, loss of cortical bone
is gradual and continues over a longer period of time compared to
trabecular and bone loss which is more rapid and severe [70]. RES
supplementation preserved mechanical strength in the femur, but not
tibia strength. In the tibia, mechanical unloading induced bone thinning
rather than bone loss as indicated by loss of trabecular thickness and con-
nectivity rather than trabecular number. RES supplementation attenuat-
ed loss of tibial BMC, BMA, cortical area, and trabecular BV/TV, thickness,
and connectivity, and increased trabecular spacing induced by HLU.
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rather than acceleration of bone resorption predominates (Fig. 1C). In
the Durbin et al. [53 ]study, old HLUmale rats provided RES exhibited el-
evated plasmaosteocalcin andALP, but hadnoeffects on plasmamarkers
of bone resorption, TRAP, DPD, and CTX. Inﬂammation was indicated by
higher plasma TNFα concentration in HLU compared to ambulatory rats.
Providing RES to old HLU male rats decreased plasma TNFα although
concentrations remained elevated compared to ambulatory rats. Based
on these results, RES supplementation attenuated inﬂammation induced
by mechanical unloading and this in turn, prevented the loss of osteo-
blasts as indicated by higher osteoblast activity.
Disuse-induced bone loss is not restricted to the elderly, but also oc-
curs in young individuals conﬁned to bed rest. To investigate this Durbin
et al. [62] chose mature (age 6 months) male Fisher 344 × Brown
Norway rats to ensure that bone loss was due to mechanical unloading
rather than aging. Using the same study design as for old rats, mature
rats were provided 12.5 mg/kg bwt/d RES for 1 week prior to HLU
and throughout the 2 weeks. HLU did not attenuate loss of trabecular
BV/TV, number, and connectivity in the femur mid-diaphysis.
Unexpectedly, HLU mature male rats provided RES had detrimental
bone effects indicated by signiﬁcantly lowered tibia BMC, Ca, cortical
thickness, and increased cortical porosity compared toHLU rat provided
no RES (Table 1). A negative correlation between plasma lipid peroxida-
tion and plasma osteocalcin concentrations (r2 = 0.69, P = 0.02) in
HLUmature rats provided RES indicated that decreased bone formation
was due to increased oxidation. Under certain conditions, RES acts as a
pro-oxidant by producing singlet oxygen that promotes lipid peroxida-
tion [72,73].
In another study, a higher dose of RES was provided for a longer-
duration prior to HLU. Habold et al. [74] provided mature (age
5 months) male Wistar rats 400 mg/kg/d RES for 4.5 weeks prior to
HLU and throughout the 2 weeks of HLU. RES supplementation
completely prevented tibial BMD loss and partially prevented BMD
loss in the femur. Providing RES attenuated loss of trabecular number,
and BV/TV and increased trabecular spacing due to HLU in the distal
femur and proximal tibia metaphysis (Table 1). Similar to the Durbin
et al. [62] study, RES supplementation had no effect on mid-diaphysis
cortical bone. Bone strength was not determined in this study. The
Momken et al. [75] study which included bone strength measurements
found that mature male Wistar rats provided with a liquid meal
consisting of 400 mg/kg bwt/d RES for 4 weeks prior to HLU and during
the 2 weeks of HLU prevented the loss of femoral BMD and preserved
bone strength (Table 1). Providing RES increased bone formation in
HLU rats as indicated by the higher plasma osteocalcin and decreased
bone resorption indicated by reduced urinary DPD.
As discussed above, RES supplementation beneﬁted old HLU rats
[53], but detrimental bone effects were observed in mature HLU rats
[62]. However, other studies that provided higher RES doses to mature
rats for a longer duration prior to HLU showed bone protective effects
(Table 1). Based on the study results, optimizing bone prior to mechan-
ical unloading protects against bone loss. Gafni et al. [76] suggested that
bone responds more to current rather than past conditions. This has
important implications for RES supplementation as a treatment for
bone injury and repair.
4.4.2. Resveratrol and injury related bone loss and bone injury repair
Bone fractures occur in 50% of individuals with complete spinal cord
injury [77]. Disuse contributes to bone loss in immobilization-related
spinal cord injury, but differs from bed rest, in that circulating bone
resorption markers are higher and bone loss is more severe [78].
Wang et al. [79] investigated the effects of RES supplementation using
a spinal cord injury model produced by complete surgical transection
of the lower thoracic cord of maturemale Sprague–Dawley rats. Twelve
hours after surgery, rats were provided 400 mg/kg bwt/d RES
intragastrically for a duration of 10 d. RES supplementation attenuated
tibial BMC and BMD loss and preserved bone microstructure indicatedby higher trabecular bone volume, number, and thickness, and lower
trabecular spacing in the metaphyseal region of the proximal tibia
compared to control rats. Histomorphometric evaluation of the tibiae
of rats provided RES showed less eroded bone surface, decreased
osteoclast surface, increased osteoblast surface, and higher tibiamineral
apposition rates. Higher serum osteocalcin and lower urinary DPD
concentrations indicated that RES supplementation preserved against
bone loss by promoting bone formation and by inhibiting bone resorp-
tion. Biomechanical strength measurements preformed on the femur
showed that RES supplementation preserved bone strength. Gene
expression analysis of the femur revealed multiple actions. RES actions
on the RANK/RANKL/OPG axis suppressed osteoclastogenesis and
promoted osteoblastogenesis indicated by down-regulation of
gene expression of the RANKL to OPG ratio and bone resorption
marker, TRAP and by up-regulation of bone formation marker,
osteocalcin (Table 1). Oxidative stress is considered a hallmark of
spinal cord injury [80]. Antioxidant actions were indicated by re-
duced serum malondialdehyde and increased serum total antioxi-
dant capacity and total sulfhydryl concentrations in spinal cord
injury rats provided RES compared to control rats. Almeida et al.
[81] reported that higher lipid oxidation in osteoblasts diminishes
Wnt signaling which activates transcription factors promotingMSC
differentiation into osteoblasts and suppresses gene expression of
PPARγ, the transcription factor that promotes differentiation of
MSC into adipocytes. Providing RES to spinal cord injured rats re-
stored Wnt1 signaling, IGF-1, and IGF-1 receptor, and down-
regulated femur PPARγ gene expression indicating RES promoted
osteoblast and inhibited adiopocyte differentiation.
To investigate the role of RES supplementation on bone repair,
Casarin et al. [82] produced a calvarial defect rat model by surgically
inserting a screw-shaped titanium implant into the tibia of mature
male Wistar rats. Following surgery, rats were provided 10 mg/kg bwt/d
RES for 30 d. Higher torque force indicated better retention of the
titanium implants in the RES-treated group. Histomorphometric evaluation
showed that RES supplementation improved bone repair indicated by re-
duced spacing in the bone margins of the calvarial defect. Up-regulation
of gene expression of bone morphogenetic protein and osteopontin in
calvarial samples indicated thatRES supplementation improvedbone repair
by promoting bone ossiﬁcation and bone tissuematuration [82]. Collective-
ly, the study results indicated that RES supplementation attenuates bone
loss induced by immobilization resulting from spinal cord injury and pro-
motes bone repair.
5. Resveratrol dose and bioavailability considerations
RES is often administered dissolved in ethanol due to poor solubility
in water. When converting doses provided to rodents based on body
weight to equivalent doses in humans, this translates into hundreds of
liters of wine per day [83]. RES doses reported to be effective for amelio-
rating bone loss in rat and mice studies ranged from 0.7 to 400 mg/kg
bwt (Table 1). Using body surface area as described by Reagan et al.
[83], this translated to doses ranging in a 60 kg human from ~7 to
3900 mg/kg bwt. RES doses above 100 mg/kg bwt Cannot be achieved
dietarily and therefore, require supplementation. Blood concentrations
provide another method for estimating effective doses. However, RES
rapid metabolism and clearance from the body leads to low plasma
RES concentrations of between 0 and 26 nM [84] which is a dose several
folds lower than required in vitro to stimulate bone cell differentiation,
proliferation, and activation [85]. Therefore, efﬁcient delivery routes
that allow for a sustained release of RES at the bone sites are
being investigated. Li et al. [85] tested a three-dimensional porous
polycaprolactone (PCL) scaffold delivery method engineered to provide
controlled release of RES in situ. In vitro, rat bone marrow stoma cell
treated with RES using PCL scaffolding exhibited increased ALP activity
and mineralization. Similarly, human bone marrow-derived MSC
treated with RES using PCL scaffolding exhibited increased ALP activity
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rats were treated with PCL scaffolding containing RES [85]. After
8 weeks, bone extracted from the skull showed that RES promoted
bone regeneration as indicated by histomorphologic andX-ray evidence
of a greater area of bone regeneration. Bone formation was indicated
by elevated bone sialoprotein concentration. Supplementation and
development of novel delivery systems can assist in overcoming issues
such as high dose requirements and low bioavailability which limits
translation of RES for human clinical use.
6. Conclusions
There is a growing body of evidence supporting the efﬁcacy of
RES supplementation for attenuating bone loss. Shown in Fig. 2, RES
inﬂuences estrogen-dependent and independent signaling transduction
pathways which modulated gene expression of transcription factors,
Runx2 and Osterix regulating osteoblast differentiation and transcrip-
tion factors, RANKL and NFκB regulating osteoclast differentiation and
activation. The ability of RES to act on both osteoblasts and osteoclasts
through multiple mechanisms suggests that RES can prevent bone loss
associated with different etiologies and pathologies. Table 1 summa-
rizes the bone physiological effects of RES supplementation in different
rodent models and potential mechanisms of action. RES supplementa-
tion prevented OVX-induced loss of bone mass, and trabecular
bone by suppressing inﬂammation which preserved bone formation.
Providing RES to aging rats prior to age-related bone loss attenuated
loss of cortical and trabecular bone by decreasing inﬂammation and
preserving bone formation. In HLU rat models, beneﬁcial or detrimental
bone effects of RES supplementation depended on dose and timing of
exposure.
Collectively, the evidence from the animal models supports a thera-
peutic value of RES supplementation on bone. However, few of the
animal studies attempted to investigate the molecular mechanisms
underlying RES anti-inﬂammatory effects on bone formation. Further
mechanistic focused studies would improve understanding as would
experimental designs using comparable doses, timing of exposure, and
treatment duration. Still, determination of a therapeutic RES dose will
ultimately require human clinical studies due to inherit limitations of
extrapolating doses found to be effective and safe in animals to humans.
Meanwhile, evidence generated by animal studies will provide the
necessary foundation for future clinical trials.
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